A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx) in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx) in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Olaparib (Primary) ; Doxorubicin liposomal
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Dec 2016 to 31 Aug 2017.
    • 21 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
    • 16 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top